Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccines
Phase of Trial: Phase IV
Latest Information Update: 18 Feb 2019
Price : $35 *
At a glance
- Drugs GSK 2321138A (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 10 Feb 2019 Status changed from recruiting to completed.
- 07 Jan 2019 Status changed from not yet recruiting to recruiting.
- 04 Oct 2018 New trial record